AstraZeneca gets FDA clearance for Fasenra

AstraZeneca has received the Food and Drug Administration’s blessing for Fasenra (benralizumab) for self-administration in a pre-filled auto-injector, the Fasenra Pen.

“Fasenra is the only respiratory biologic that can be given every eight weeks after the initial loading-dose period. Today’s news means we can now offer Fasenra in an even more convenient way, giving U.S. healthcare providers and patients the option of administering Fasenra at home or in a doctor’s office, and making treatment more accessible to patients with severe eosinophilic asthma,” BioPharmaceuticals R&D executive vice president Mene Pangalos said.

“As a clinician, I use Fasenra in my office because of its efficacy and safety data. The importance of this approval is that my patients and I now have another option to personalize their treatment approach to help meet their needs and fit their lifestyle,” said Reynold Panettieri, vice chancellor for translational medicine and science and director of Rutgers Institute for Translational Medicine and Science.